Jump to content

Phosphoinositide 3-kinase

From Wikipedia, the free encyclopedia
(Redirected from PI-3 kinase)
"PIK3" redirects here. For the Finnish sailplane, see PIK-3.
Phosphatidylinositol-4,5-bisphosphate 3-kinase
PIK-93 inhibitor (yellow) bound to the PI3K 110 gamma subunit .[1]
Identifiers
SymbolPI3K
PfamPF00454
InterProIPR000403
SMARTSM00146
PROSITEPDOC00710
SCOP23gmm / SCOPe / SUPFAM
OPM superfamily265
OPM protein3ml9
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
Phosphoinositide 3-kinase
Identifiers
EC no.2.7.1.137
CAS no.115926-52-8
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Search
PMCarticles
PubMedarticles
NCBIproteins

Phosphoinositide 3-kinases (PI3Ks), also called phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.

PI3Ks are a family of related intracellular signal transducer enzymes capable of phosphorylating the 3 position hydroxyl group of the inositol ring of phosphatidylinositol (PtdIns).[2] The pathway, with oncogene PIK3CA and tumor suppressor gene PTEN, is implicated in the sensitivity of cancer tumors to insulin and IGF1, and in calorie restriction.[3][4]

Discovery

[edit]

The discovery of PI3Ks by Lewis Cantley and colleagues began with their identification of a previously unknown phosphoinositide kinase associated with the polyoma middle T protein.[5] They observed unique substrate specificity and chromatographic properties of the products of the lipid kinase, leading to the discovery that this phosphoinositide kinase had the unprecedented ability to phosphorylate phosphoinositides on the 3' position of the inositol ring.[6] Subsequently, Cantley and colleagues demonstrated that in vivo the enzyme prefers PtdIns(4,5)P2 as a substrate, producing the novel phosphoinositide PtdIns(3,4,5)P3[7] previously identified in neutrophils.[8]

Classes

[edit]

The PI3K family is divided into four different classes: Class I, Class II, Class III, and Class IV. The classifications are based on primary structure, regulation, and in vitro lipid substrate specificity.[9]

Class I

[edit]

Class I PI3Ks catalyze the conversion of phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) into phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) in vivo. While in vitro, they have also been shown to convert phosphatidylinositol (PI) into phosphatidylinositol 3-phosphate (PI3P) and phosphatidylinositol 4-phosphate (PI4P) into phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2), these reactions are strongly disfavoured in vivo.[10][11][12][13] The PI3K is activated by G protein-coupled receptors and tyrosine kinase receptors.[9]

Class I PI3Ks are heterodimeric molecules composed of a regulatory and a catalytic subunit; they are further divided between IA and IB subsets on sequence similarity. Class IA PI3Ks are composed of a heterodimer between a p110 catalytic subunit and a shorter regulatory subunit (often p85).[14] There are five variants of the regulatory subunit: the three splice variants p85α, p55α, and p50α, p85β, and p55γ. There are also three variants of the p110 catalytic subunit designated p110α, β, or δ catalytic subunit. The first three regulatory subunits are all splice variants of the same gene (Pik3r1), the other two being expressed by other genes (Pik3r2 and Pik3r3, p85β, and p55γ, respectively). The most highly expressed regulatory subunit is p85α; all three catalytic subunits are expressed by separate genes (Pik3ca, Pik3cb, and Pik3cd for p110α, p110β, and p110δ, respectively). The first two p110 isoforms (α and β) are expressed in all cells, but p110δ is expressed primarily in leukocytes, and it has been suggested that it evolved in parallel with the adaptive immune system. The regulatory p101 and catalytic p110γ subunits comprise the class IB PI3Ks and are encoded by a single gene each (Pik3cg for p110γ and Pik3r5 for p101).

The p85 subunits contain SH2 and SH3 domains (Online Mendelian Inheritance in Man (OMIM): 171833). The SH2 domains bind preferentially to phosphorylated tyrosine residues in the amino acid sequence context Y-X-X-M.[15][16]

Classes II and III

[edit]
Overview of signal transduction pathways involved in apoptosis.

Class II and III PI3Ks are differentiated from the Class I by their structure and function. The distinct feature of Class II PI3Ks is the C-terminal C2 domain. This domain lacks critical Asp residues to coordinate binding of Ca2+, which suggests class II PI3Ks bind lipids in a Ca2+-independent manner.

Class II comprises three catalytic isoforms (C2α, C2β, and C2γ), but, unlike Classes I and III, no regulatory proteins. Class II catalyse the production of PI(3)P from PI and PI(3,4)P2 from PI(4)P; however, little is known about their role in immune cells. PI(3,4)P2 has, however, been shown to play a role in the invagination phase of clathrin-mediated endocytosis.[17] C2α and C2β are expressed through the body, but expression of C2γ is limited to hepatocytes.

Class III PI3Ks produce only PI(3)P from PI [9] but are more similar to Class I in structure, as they exist as heterodimers of a catalytic (Vps34) and a regulatory (Vps15/p150) subunits. Class III seems to be primarily involved in the trafficking of proteins and vesicles. There is, however, evidence to show that they are able to contribute to the effectiveness of several process important to immune cells, not least phagocytosis.

Class IV

[edit]
Main article: Phosphatidylinositol 3-kinase-related kinase

A group of more distantly related enzymes is sometimes referred to as class IV PI3Ks. It is composed of ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR). They are protein serine/threonine kinases.

Human genes

[edit]
group gene protein aliases EC number
class 1 catalytic PIK3CA PI3K, catalytic, alpha polypeptide p110-α 2.7.1.153
PIK3CB PI3K, catalytic, beta polypeptide p110-β
PIK3CG PI3K, catalytic, gamma polypeptide p110-γ
PIK3CD PI3K, catalytic, delta polypeptide p110-δ
class 1 regulatory PIK3R1 PI3K, regulatory subunit 1 (alpha) p85-α, p55-α, p50-α (splice variants) N/A
PIK3R2 PI3K, regulatory subunit 2 (beta) p85-β
PIK3R3 PI3K, regulatory subunit 3 (gamma) p55-γ
PIK3R4 PI3K, regulatory subunit 4 p150
PIK3R5 PI3K, regulatory subunit 5 p101
PIK3R6 PI3K, regulatory subunit 6 p87
class 2 PIK3C2A PI3K, class 2, alpha polypeptide PI3K-C2α 2.7.1.154
PIK3C2B PI3K, class 2, beta polypeptide PI3K-C2β
PIK3C2G PI3K, class 2, gamma polypeptide PI3K-C2γ
class 3 PIK3C3 PI3K, class 3 Vps34 2.7.1.137

Mechanism

[edit]

The various 3-phosphorylated phosphoinositides that are produced by PI3Ks (PtdIns3P, PtdIns(3,4)P2, PtdIns(3,5)P2, and PtdIns(3,4,5)P3) function in a mechanism by which an assorted group of signalling proteins, containing PX domains, pleckstrin homology domains (PH domains), FYVE domains or other phosphoinositide-binding domains, are recruited to various cellular membranes.

Function

[edit]

PI3Ks have been linked to an extraordinarily diverse group of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Many of these functions relate to the ability of class I PI3Ks to activate protein kinase B (PKB, aka Akt) as in the PI3K/AKT/mTOR pathway. The p110δ and p110γ isoforms regulate different aspects of immune responses. PI3Ks are also a key component of the insulin signaling pathway. Hence there is great interest in the role of PI3K signaling in diabetes mellitus. PI3K is also involved in interleukin signalling (IL4)[citation needed]

Mechanism

[edit]

The pleckstrin homology domain of AKT binds directly to PtdIns(3,4,5)P3 and PtdIns(3,4)P2, which are produced by activated PI3Ks.[18] Since PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are restricted to the plasma membrane, this results in translocation of AKT to the plasma membrane. Likewise, the phosphoinositide-dependent kinase-1 (PDK1 or, rarely referred to as PDPK1) also contains a pleckstrin homology domain that binds directly to PtdIns(3,4,5)P3 and PtdIns(3,4)P2, causing it to also translocate to the plasma membrane upon PI3K activation. The interaction of activated PDK1 and AKT allows AKT to become phosphorylated by PDK1 on threonine 308, leading to partial activation of AKT. Full activation of AKT occurs upon phosphorylation of serine 473 by the TORC2 complex of the mTOR protein kinase.

The PI3K/AKT pathway has been shown to be required for an extremely diverse array of cellular activities - most notably cellular proliferation and survival. For example, it was shown to be involved in the protection of astrocytes from ceramide-induced apoptosis.[19]

Many other proteins have been identified that are regulated by PtdIns(3,4,5)P3, including Bruton's tyrosine kinase (BTK), General Receptor for Phosphoinositides-1 (GRP1), and the O-linked N-acetylglucosamine (O-GlcNAc) transferase.

PtdIns(3,4,5)P3 also activates guanine‐nucleotide exchange factors (GEFs) that activate the GTPase Rac1,[20] leading to actin polymerization and cytoskeletal rearrangement.[21]

Cancers

[edit]

The class IA PI3K p110α is mutated in many cancers. Many of these mutations cause the kinase to be more active. It is the single most mutated kinase in glioblastoma, the most malignant primary brain tumor.[22] The PtdIns(3,4,5)P3 phosphatase PTEN that antagonises PI3K signaling is absent from many tumours. In addition, the epidermal growth factor receptor EGFR that functions upstream of PI3K is mutationally activated or overexpressed in cancer.[22][23] Hence, PI3K activity contributes significantly to cellular transformation and the development of cancer. It has been shown that malignant B cells maintain a "tonic" activity of PI3K/Akt axis via upregulation of an adaptor protein GAB1, and this also allows B cells to survive targeted therapy with BCR inhibitors.[citation needed]

Learning and memory

[edit]

PI3Ks have also been implicated in long-term potentiation (LTP). Whether they are required for the expression or the induction of LTP is still debated. In mouse hippocampal CA1 neurons, certain PI3Ks are complexed with AMPA receptors and compartmentalized at the postsynaptic density of glutamatergic synapses.[24] PI3Ks are phosphorylated upon NMDA receptor-dependent CaMKII activity,[25] and it then facilitates the insertion of AMPA-R GluR1 subunits into the plasma membrane. This suggests that PI3Ks are required for the expression of LTP. Furthermore, PI3K inhibitors abolished the expression of LTP in rat hippocampal CA1, but do not affect its induction.[26] Notably, the dependence of late-phase LTP expression on PI3Ks seems to decrease over time.[27]

However, another study found that PI3K inhibitors suppressed the induction, but not the expression, of LTP in mouse hippocampal CA1.[28] The PI3K pathway also recruits many other proteins downstream, including mTOR,[29] GSK3β,[30] and PSD-95.[29] The PI3K-mTOR pathway leads to the phosphorylation of p70S6K, a kinase that facilitates translational activity,[31][32] further suggesting that PI3Ks are required for the protein-synthesis phase of LTP induction instead.

PI3Ks interact with the insulin receptor substrate (IRS) to regulate glucose uptake through a series of phosphorylation events.

PI 3-kinases as protein kinases

[edit]

Many PI3Ks appear to have a serine/threonine kinase activity in vitro; however, it is unclear whether this has any role in vivo.[citation needed]

Inhibition

[edit]

All PI3Ks are inhibited by the drugs wortmannin and LY294002, although certain members of the class II PI3K family show decreased sensitivity. Wortmannin shows better efficiency than LY294002 on the hotspot mutation positions (GLU542, GLU545, and HIS1047)[33][34]

PI3K inhibitors as therapeutics

[edit]
Main article: PI3K inhibitor

As wortmannin and LY294002 are broad-range inhibitors of PI3Ks and a number of unrelated proteins at higher concentrations, they are too toxic to be used as therapeutics.[citation needed] A number of pharmaceutical companies have thus developed PI3K isoform-specific inhibitors. As of January 2019, three PI3K inhibitors are approved by the FDA for routine clinical use in humans: the PIK3CD inhibitor idelalisib (July 2014, NDA 206545), the dual PIK3CA and PIK3CD inhibitor copanlisib (September 2017, NDA 209936), and the dual PIK3CD and PIK3CG inhibitor duvelisib (September 2018, NDA 211155). Co-targeted inhibition of the pathway with other pathways such as MAPK or PIM has been highlighted as a promising anti-cancer therapeutic strategy, which could offer benefit over the monotherapeutic approach by circumventing compensatory signalling, slowing the development of resistance and potentially allowing reduction of dosing.[35][36][37][38][39]

See also

[edit]

References

[edit]
  1. ^ PDB: 2chz​; Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. (May 2006). "A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling". Cell. 125 (4): 733–47. doi:10.1016/j.cell.2006.03.035. PMC 2946820. PMID 16647110.
  2. ^ "myo-inositol". Archived from the original on 2011-08-06. Retrieved 2006-01-28.
  3. ^ Giese N (2009). "Cell pathway on overdrive prevents cancer response to dietary restriction". PhysOrg.com. Retrieved 2009-04-22.
  4. ^ Kalaany NY, Sabatini DM (April 2009). "Tumours with PI3K activation are resistant to dietary restriction". Nature. 458 (7239): 725–31. Bibcode:2009Natur.458..725K. doi:10.1038/nature07782. PMC 2692085. PMID 19279572.
  5. ^ Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985). "Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation". Nature. 315 (6016): 239–42. Bibcode:1985Natur.315..239W. doi:10.1038/315239a0. PMID 2987699. S2CID 4337999.
  6. ^ Whitman M, Downes CP, Keeler M, Keller T, Cantley L (April 1988). "Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate". Nature. 332 (6165): 644–6. Bibcode:1988Natur.332..644W. doi:10.1038/332644a0. PMID 2833705. S2CID 4326568.
  7. ^ Auger KR, Serunian LA, Soltoff SP, Libby P, Cantley LC (April 1989). "PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells". Cell. 57 (1): 167–75. doi:10.1016/0092-8674(89)90182-7. PMID 2467744. S2CID 22154860.
  8. ^ Traynor-Kaplan AE, Harris AL, Thompson BL, Taylor P, Sklar LA (July 1988). "An inositol tetrakisphosphate-containing phospholipid in activated neutrophils". Nature. 334 (6180): 353–6. Bibcode:1988Natur.334..353T. doi:10.1038/334353a0. PMID 3393226. S2CID 4263472.
  9. ^ a b c Leevers SJ, Vanhaesebroeck B, Waterfield MD (April 1999). "Signalling through phosphoinositide 3-kinases: the lipids take centre stage". Current Opinion in Cell Biology. 11 (2): 219–25. doi:10.1016/S0955-0674(99)80029-5. PMID 10209156.
  10. ^ Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (August 2017). "The PI3K Pathway in Human Disease". Cell. 170 (4): 605–635. doi:10.1016/j.cell.2017.07.029. PMC 5726441. PMID 28802037.
  11. ^ Jean S, Kiger AA (March 2014). "Classes of phosphoinositide 3-kinases at a glance". Journal of Cell Science. 127 (Pt 5): 923–8. doi:10.1242/jcs.093773. PMC 3937771. PMID 24587488.
  12. ^ Vanhaesebroeck B, Stephens L, Hawkins P (February 2012). "PI3K signalling: the path to discovery and understanding". Nature Reviews. Molecular Cell Biology. 13 (3): 195–203. doi:10.1038/nrm3290. PMID 22358332. S2CID 6999833.
  13. ^ Okkenhaug K (January 2013). "Signaling by the phosphoinositide 3-kinase family in immune cells". Annual Review of Immunology. 31 (2): 675–704. doi:10.1146/annurev-immunol-032712-095946. PMC 4516760. PMID 23330955.
  14. ^ Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (November 1990). "Purification and characterization of phosphoinositide 3-kinase from rat liver". The Journal of Biological Chemistry. 265 (32): 19704–11. doi:10.1016/S0021-9258(17)45429-9. PMID 2174051.
  15. ^ Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. (March 1993). "SH2 domains recognize specific phosphopeptide sequences". Cell. 72 (5): 767–78. doi:10.1016/0092-8674(93)90404-E. PMID 7680959.
  16. ^ Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B (September 1994). "Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity". Molecular and Cellular Biology. 14 (9): 5929–38. doi:10.1128/MCB.14.9.5929. PMC 359119. PMID 8065326.
  17. ^ Posor Y, Eichhorn-Grünig M, Haucke V (June 2015). "Phosphoinositides in endocytosis". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1851 (6): 794–804. doi:10.1016/j.bbalip.2014.09.014. PMID 25264171.
  18. ^ Franke TF, Kaplan DR, Cantley LC, Toker A (January 1997). "Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate". Science. 275 (5300): 665–8. doi:10.1126/science.275.5300.665. PMID 9005852. S2CID 31186873.
  19. ^ Gómez Del Pulgar T, De Ceballos ML, Guzmán M, Velasco G (September 2002). "Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway". The Journal of Biological Chemistry. 277 (39): 36527–33. doi:10.1074/jbc.M205797200. PMID 12133838.
  20. ^ Welch HC, Coadwell WJ, Stephens LR, Hawkins PT (July 2003). "Phosphoinositide 3-kinase-dependent activation of Rac". FEBS Letters. 546 (1): 93–7. doi:10.1016/s0014-5793(03)00454-x. PMID 12829242.
  21. ^ Jaffe AB, Hall A (2005). "Rho GTPases: biochemistry and biology". Annual Review of Cell and Developmental Biology. 21: 247–69. doi:10.1146/annurev.cellbio.21.020604.150721. PMID 16212495.
  22. ^ a b Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, et al. (September 2014). "Mutational profiling of kinases in glioblastoma". BMC Cancer. 14: 718. doi:10.1186/1471-2407-14-718. PMC 4192443. PMID 25256166.
  23. ^ Bleeker FE, Molenaar RJ, Leenstra S (May 2012). "Recent advances in the molecular understanding of glioblastoma". Journal of Neuro-Oncology. 108 (1): 11–27. doi:10.1007/s11060-011-0793-0. PMC 3337398. PMID 22270850.
  24. ^ Man HY, Wang Q, Lu WY, Ju W, Ahmadian G, Liu L, et al. (May 2003). "Activation of PI3-kinase is required for AMPA receptor insertion during LTP of mEPSCs in cultured hippocampal neurons". Neuron. 38 (4): 611–24. doi:10.1016/S0896-6273(03)00228-9. PMID 12765612.
  25. ^ Joyal JL, Burks DJ, Pons S, Matter WF, Vlahos CJ, White MF, Sacks DB (November 1997). "Calmodulin activates phosphatidylinositol 3-kinase". The Journal of Biological Chemistry. 272 (45): 28183–6. doi:10.1074/jbc.272.45.28183. PMID 9353264.
  26. ^ Sanna PP, Cammalleri M, Berton F, Simpson C, Lutjens R, Bloom FE, Francesconi W (May 2002). "Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region". The Journal of Neuroscience. 22 (9): 3359–65. doi:10.1523/JNEUROSCI.22-09-03359.2002. PMC 6758361. PMID 11978812.
  27. ^ Karpova A, Sanna PP, Behnisch T (February 2006). "Involvement of multiple phosphatidylinositol 3-kinase-dependent pathways in the persistence of late-phase long term potentiation expression". Neuroscience. 137 (3): 833–41. doi:10.1016/j.neuroscience.2005.10.012. PMID 16326012. S2CID 38232127.
  28. ^ Opazo P, Watabe AM, Grant SG, O'Dell TJ (May 2003). "Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms". The Journal of Neuroscience. 23 (9): 3679–88. doi:10.1523/JNEUROSCI.23-09-03679.2003. PMC 6742185. PMID 12736339.
  29. ^ a b Yang PC, Yang CH, Huang CC, Hsu KS (February 2008). "Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity". The Journal of Biological Chemistry. 283 (5): 2631–43. doi:10.1074/jbc.M706954200. PMID 18057005.
  30. ^ Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, et al. (March 2007). "LTP inhibits LTD in the hippocampus via regulation of GSK3beta". Neuron. 53 (5): 703–17. doi:10.1016/j.neuron.2007.01.029. PMID 17329210. S2CID 6903401.
  31. ^ Toker A, Cantley LC (June 1997). "Signalling through the lipid products of phosphoinositide-3-OH kinase". Nature. 387 (6634): 673–6. Bibcode:1997Natur.387..673T. doi:10.1038/42648. PMID 9192891. S2CID 4347728.
  32. ^ Cammalleri M, Lütjens R, Berton F, King AR, Simpson C, Francesconi W, Sanna PP (November 2003). "Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1". Proceedings of the National Academy of Sciences of the United States of America. 100 (24): 14368–73. Bibcode:2003PNAS..10014368C. doi:10.1073/pnas.2336098100. PMC 283598. PMID 14623952.
  33. ^ Kumar DT, Doss CG (2016-01-01). Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach. Vol. 102. pp. 267–97. doi:10.1016/bs.apcsb.2015.09.008. ISBN 9780128047958. PMID 26827608. {{cite book}}: |journal= ignored (help)
  34. ^ Sudhakar N, Priya Doss CG, Thirumal Kumar D, Chakraborty C, Anand K, Suresh M (2016-01-02). "Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach". Journal of Biomolecular Structure & Dynamics. 34 (1): 29–41. doi:10.1080/07391102.2015.1007483. PMID 25679319. S2CID 205575161.
  35. ^ Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, et al. (March 2020). "Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer" (PDF). Pharmacology & Therapeutics. 207: 107454. doi:10.1016/j.pharmthera.2019.107454. PMID 31836451. S2CID 209357486.
  36. ^ Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S (2020). "PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer". Signal Transduction and Targeted Therapy. 5: 7. doi:10.1038/s41392-020-0109-y. PMC 6992635. PMID 32025342.
  37. ^ Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, et al. (January 2018). "Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines". Scientific Reports. 8 (1): 1652. Bibcode:2018NatSR...8.1652H. doi:10.1038/s41598-018-19688-1. PMC 5786033. PMID 29374181.
  38. ^ Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, et al. (October 2014). "Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC". Cancer Biology & Therapy. 15 (10): 1367–77. doi:10.4161/cbt.29841. PMC 4130730. PMID 25025901.
  39. ^ Heavey S, O'Byrne KJ, Gately K (April 2014). "Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC". Cancer Treatment Reviews. 40 (3): 445–56. doi:10.1016/j.ctrv.2013.08.006. PMID 24055012.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Phosphoinositide_3-kinase&oldid=1186056681"